DK214088A - Ae6-heterobiskcyclisk substituerede 2(1h)-quinolon-forbindelser og deres anvendelse som hjertestimulerende midler samt farmaceutiske praeparater indeholdende disseae - Google Patents
Ae6-heterobiskcyclisk substituerede 2(1h)-quinolon-forbindelser og deres anvendelse som hjertestimulerende midler samt farmaceutiske praeparater indeholdende disseaeInfo
- Publication number
- DK214088A DK214088A DK214088A DK214088A DK214088A DK 214088 A DK214088 A DK 214088A DK 214088 A DK214088 A DK 214088A DK 214088 A DK214088 A DK 214088A DK 214088 A DK214088 A DK 214088A
- Authority
- DK
- Denmark
- Prior art keywords
- stiments
- heterobiscyclic
- cardiental
- dissert
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB878709448A GB8709448D0 (en) | 1987-04-21 | 1987-04-21 | Heterobicyclic quinoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK214088D0 DK214088D0 (da) | 1988-04-20 |
| DK214088A true DK214088A (da) | 1988-12-07 |
Family
ID=10616116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK214088A DK214088A (da) | 1987-04-21 | 1988-04-20 | Ae6-heterobiskcyclisk substituerede 2(1h)-quinolon-forbindelser og deres anvendelse som hjertestimulerende midler samt farmaceutiske praeparater indeholdende disseae |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4898872A (da) |
| EP (1) | EP0290153A1 (da) |
| JP (1) | JPS63280078A (da) |
| DK (1) | DK214088A (da) |
| FI (1) | FI881825A (da) |
| GB (1) | GB8709448D0 (da) |
| PT (1) | PT87273A (da) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3932953A1 (de) * | 1989-10-03 | 1991-04-11 | Boehringer Mannheim Gmbh | Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| WO1991012251A1 (en) * | 1990-02-19 | 1991-08-22 | Chugai Seiyaku Kabushiki Kaisha | Novel fused heterocyclic compound and antiasthmatic agent prepared therefrom |
| US6465484B1 (en) | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
| US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CA2333643A1 (en) * | 1998-06-30 | 2000-01-06 | James D. Rodgers | Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors |
| US6127382A (en) * | 1999-08-16 | 2000-10-03 | Allergan Sales, Inc. | Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| US6613917B1 (en) | 2000-03-23 | 2003-09-02 | Allergan, Inc. | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| US6528649B2 (en) | 2000-05-30 | 2003-03-04 | Neurogen Corporation | Imidazoloisoquinolines |
| WO2002018383A2 (en) | 2000-09-01 | 2002-03-07 | Chiron Corporation | Aza heterocyclic derivatives and their therapeutic use |
| ES2302106T3 (es) * | 2000-09-11 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina. |
| AU2003288899B2 (en) | 2002-08-23 | 2009-09-03 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| BR0316229A (pt) | 2002-11-13 | 2005-10-04 | Chiron Corp | Métodos de tratamento de câncer e métodos relacionados |
| EP2174933B1 (en) * | 2003-03-13 | 2019-04-03 | Idemitsu Kosan Co., Ltd. | Benzimidazole derivatives for use in organic electroluminescent devices |
| RU2377988C2 (ru) | 2004-02-20 | 2010-01-10 | Новартис Вэксинес Энд Дайэгностикс, Инк. | Модуляция воспалительных и метастатических процессов |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7645881B2 (en) | 2004-07-22 | 2010-01-12 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| CA2580852A1 (en) * | 2004-09-21 | 2006-03-30 | Synta Pharmaceutical Corp. | Compounds for inflammation and immune-related uses |
| AU2006247803B2 (en) | 2005-05-13 | 2011-12-22 | Novartis Ag | Methods for treating drug resistant cancer |
| BRPI0610355A2 (pt) | 2005-05-17 | 2010-06-15 | Novartis Ag | métodos par sintetizar compostos heterocìclicos |
| AU2006249847B2 (en) | 2005-05-23 | 2012-12-20 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts |
| ATE543819T1 (de) * | 2006-10-19 | 2012-02-15 | Signal Pharm Llc | Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit |
| DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| MX315904B (es) | 2008-05-30 | 2013-11-29 | Amgen Inc | Inhibidores de fosfoinosituro-3 cinasa. |
| EP2348018A4 (en) | 2008-09-25 | 2012-04-25 | Kyorin Seiyaku Kk | HETEROCYCLIC BIARYLIC DERIVATIVE AND PDE INHIBITOR COMPRISING THE SAME AS ACTIVE INGREDIENT |
| US20110224250A1 (en) * | 2008-10-09 | 2011-09-15 | Yasushi Kohno | Isoquinoline derivative, and pde inhibitor comprising same as active ingredient |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| WO2011021678A1 (ja) * | 2009-08-21 | 2011-02-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| JP2013508456A (ja) | 2009-10-26 | 2013-03-07 | シグナル ファーマシューティカルズ， エルエルシー | ヘテロアリール化合物の合成方法および精製方法 |
| US9353081B2 (en) | 2011-09-23 | 2016-05-31 | Hoffmann-La Roche Inc. | Bicyclic dihydroquinoline-2-one derivatives |
| ES2894958T3 (es) | 2011-10-19 | 2022-02-16 | Signal Pharm Llc | Tratamiento del cáncer con inhibidores de la quinasa TOR |
| KR102040997B1 (ko) | 2011-12-02 | 2019-11-27 | 시그날 파마소티칼 엘엘씨 | 7-(6-(2-히드록시프로판-2-일)피리딘-3-일)-1-((트랜스)-4-메톡시시클로헥실)-3,4-디히드로피라지노[2,3-b]피라진-2(1H)-온, 그의 고체 형태의 제약 조성물 및 그의 사용 방법 |
| US9375443B2 (en) | 2012-02-24 | 2016-06-28 | Signal Pharmaceuticals, Llc | Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| EP3202403A1 (en) | 2013-01-16 | 2017-08-09 | Signal Pharmaceuticals, LLC | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| JP6382949B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ，エルエルシー | 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法 |
| CN105324381A (zh) | 2013-04-17 | 2016-02-10 | 西格诺药品有限公司 | 有关1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氢吡嗪并[2,3-b]吡嗪-2(1H)-酮的药物制剂、程序、固体形式和使用方法 |
| JP6382945B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ，エルエルシー | ジヒドロピラジノ−ピラジンによる癌治療 |
| KR20160002792A (ko) | 2013-04-17 | 2016-01-08 | 시그날 파마소티칼 엘엘씨 | 암 치료용 tor 키나제 억제제 및 n-(3-(5-플루오로-2-(4-(2-메톡시에톡시)페닐아미노)피리미딘-4-일아미노)페닐)아크릴아미드를 포함하는 병용 요법 |
| TWI631949B (zh) | 2013-04-17 | 2018-08-11 | 標誌製藥公司 | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| CA2908957C (en) | 2013-04-17 | 2021-05-18 | Signal Pharmaceuticals, Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| TWI656875B (zh) | 2013-04-17 | 2019-04-21 | 美商標誌製藥公司 | 藉二氫吡并吡治療癌症 |
| JPWO2014174745A1 (ja) * | 2013-04-26 | 2017-02-23 | 国立大学法人京都大学 | Ｅｇ５阻害剤 |
| WO2014193912A1 (en) | 2013-05-29 | 2014-12-04 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
| JP2017514806A (ja) | 2014-04-16 | 2017-06-08 | シグナル ファーマシューティカルズ，エルエルシー | Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法 |
| US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| US9623028B2 (en) | 2014-07-14 | 2017-04-18 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| JP6702956B2 (ja) | 2014-10-10 | 2020-06-03 | サビック グローバル テクノロジーズ ベスローテン フェンノートシャップ | ポリエーテルイミドワニス組成物、その製造方法およびそれから製造される物品 |
| WO2018237114A1 (en) | 2017-06-22 | 2018-12-27 | Celgene Corporation | TREATMENT OF HEPATOCELLULAR CARCINOMA CHARACTERIZED BY HEPATITIS B VIRUS INFECTION |
| EP3679028A1 (en) * | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydroquinolinones |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1164459A (en) * | 1980-11-11 | 1984-03-27 | Yung-Hsiung Yang | Process for preparing (imidazo¬1,2-a|pyridine- 2-yl)-carbostyril or -3,4-dihydrocarbostyryl derivatives |
| JPS5782390A (en) * | 1980-11-11 | 1982-05-22 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
| FI77852C (fi) * | 1981-02-17 | 1989-05-10 | Otsuka Pharma Co Ltd | Foerfarande foer framstaellning av nya, saosom hjaertmediciner anvaendbara substituerade amid- och (maettad heterocykel)karbonylkarbostyrilderivat. |
| US4710507A (en) * | 1983-12-22 | 1987-12-01 | Pfizer Inc. | Quinolone inotropic agents |
| ES8608874A1 (es) * | 1984-05-29 | 1986-09-01 | Pfizer | Un procedimiento para la preparacion de una 2-(1h)-quinolona |
| GB8502267D0 (en) * | 1985-01-30 | 1985-02-27 | Pfizer Ltd | Quinolone inotropic agents |
| JPH0662608B2 (ja) * | 1985-08-26 | 1994-08-17 | 大塚製薬株式会社 | カルボスチリル誘導体 |
| GB8529362D0 (en) * | 1985-11-28 | 1986-01-02 | Pfizer Ltd | Quinolone cardiac stimulants |
| JPS63301821A (ja) * | 1986-03-05 | 1988-12-08 | Otsuka Pharmaceut Co Ltd | 抗不整脈剤 |
| JPH07121937B2 (ja) * | 1987-03-18 | 1995-12-25 | 大塚製薬株式会社 | カルボスチリル誘導体 |
-
1987
- 1987-04-21 GB GB878709448A patent/GB8709448D0/en active Pending
-
1988
- 1988-04-15 EP EP88303410A patent/EP0290153A1/en not_active Withdrawn
- 1988-04-19 PT PT87273A patent/PT87273A/pt not_active Application Discontinuation
- 1988-04-19 FI FI881825A patent/FI881825A/fi not_active Application Discontinuation
- 1988-04-20 DK DK214088A patent/DK214088A/da not_active Application Discontinuation
- 1988-04-21 US US07/184,462 patent/US4898872A/en not_active Expired - Fee Related
- 1988-04-21 JP JP63099280A patent/JPS63280078A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB8709448D0 (en) | 1987-05-28 |
| EP0290153A1 (en) | 1988-11-09 |
| DK214088D0 (da) | 1988-04-20 |
| FI881825A (fi) | 1988-10-22 |
| FI881825A0 (fi) | 1988-04-19 |
| US4898872A (en) | 1990-02-06 |
| PT87273A (pt) | 1988-05-01 |
| JPS63280078A (ja) | 1988-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK214088D0 (da) | Ae6-heterobiskcyclisk substituerede 2(1h)-quinolon-forbindelser og deres anvendelse som hjertestimulerende midler samt farmaceutiske praeparater indeholdende disseae | |
| NO882075D0 (no) | 9-alfa-hydroksysteroider, deres fremstilling, en fremgangsmaate for fremstilling av de tilsvarende 9(11)-dehydro-derivater samt farmasoeytiske preparater inneholdend | |
| DK154085A (da) | N-aryl-n-(4-piperidinyl)-amider samt farmaceutiske praeparater deraf | |
| DK289487A (da) | Farmaceutiske praeparater til topisk applikation samt deres fremstilling og anvendelse | |
| DK25992D0 (da) | Quinolinderivater, deres fremstilling samt farmaeutisk praeparat indeholdende saadanne derivater | |
| DK422485D0 (da) | 1,3-diacyl-2-oxindol-forbindelser og mellemprodukter ved deres fremstilling samt farmaceutiske praeparater | |
| DK705488D0 (da) | Farmaceutisk praeparat | |
| DK413987D0 (da) | Farmaceutiske praeparater | |
| DK568285D0 (da) | 1,4-dihydropyridiner, deres fremstilling og mellemprodukter hertil samt deres anvendelse som laegemidler | |
| DK287188D0 (da) | Cephalosporinforbindelser og farmaceutisk praeparat deraf | |
| DK435688A (da) | Farmaceutiske midler | |
| DK652787D0 (da) | Farmaceutiske praeparater | |
| DK143188D0 (da) | Farmaceutiske praeparater indeholdende pyranoquinolinforbindelser samt deres anvendelse | |
| DK52086A (da) | Farmaceutiske praeparater indeholdende ergotalkaloider | |
| DK447887A (da) | Frysetoerrede farmaceutiske praeparater | |
| DK139388A (da) | Farmaceutisk praeparat | |
| DK172486D0 (da) | Heterocyclyl-penem-forbindelser samt deres fremstilling og anvendelse | |
| DK276288A (da) | Farmaceutisk praeparat | |
| DK439588D0 (da) | Beta-lactamer, fremgangsmaade til deres fremstilling, mellemprodukter til brug derved og farmaceutiske praeparater indeholdende forbindelserne | |
| DK534586D0 (da) | Insecticide og acaricide phenoxypyridinylestere samt mellemproduktertil deres fremstilling | |
| DK465786D0 (da) | Phenoxyforbindelser samt deres fremstilling og anvendelse | |
| DK206686A (da) | Acylaminomethyl-penem-forbindelser samt deres fremstilling og anvendelse | |
| DK138888A (da) | Farmaceutisk praeparat | |
| FR2587217B1 (fr) | Preparations pharmaceutiques immunomodulantes | |
| DK13588D0 (da) | Heterocyclylalkyl-2-penem-forbindelser samt deres fremstilling og anvendelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHB | Application shelved due to non-payment |